Group 1 - The company, He Yu-B, repurchased 84,000 shares at an average price of HKD 11.03 per share, totaling approximately HKD 926,600, with a cumulative repurchase of 9.829 million shares this year, representing 1.46% of the total share capital [1] - As of the market close on the same day, He Yu-B's stock price increased by 9.95%, reaching HKD 11.49 per share [1] - Stock repurchase is generally viewed as a positive signal from the company, indicating management's confidence in future development and potentially signaling that the stock is undervalued [1] Group 2 - He Yu-B is a Hong Kong-listed biopharmaceutical company focused on the research and development of innovative drugs for oncology and autoimmune diseases [2] - The company invests significantly in drug development, with a pipeline that includes multiple promising drug projects addressing unmet medical needs [2] - He Yu-B holds a certain position in the industry due to its research and innovation capabilities, although its operational status and future prospects are influenced by various factors such as research outcomes, clinical trial progress, market competition, and policy environment [2]
和誉-B回购8.40万股股票，共耗资约92.66万港元，本年累计回购982.90万股